Search clinical trials for: Cetuximab (Erbitux®)

Total 16593 results

Emory University
Novartis

Completed

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Head and Neck Neoplasms | Cancer of the Head and Neck

United States
Mabion SA
Parexel

Withdrawn

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis (MABRIDGE)

Rheumatoid Arthritis
GCS IHFB Cognacq-Jay

Recruiting

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL)

Cancer Colorectal

France
University of Tennessee Cancer Institute
National Comprehensive Cancer Network

Terminated

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

Switzerland, France, Austria, Germany, Hungary
Association pour la Recherche sur le Temps Biologique...
Pfizer; Merck Serono International SA; Gustave Roussy, Cancer Campus, Grand Paris and other collaborators

Unknown

Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy (OPTILIV)

Metastatic Colorectal Cancer | Liver Metastases | Hepatic Lesions

France, Italy, Belgium, Portugal
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
Austin Health
Royal North Shore Hospital; Ballarat Health Services; Queen Elizabeth Hospital...

Unknown

Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib (Dux)

Metastatic Colorectal Cancer

Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditions

United States
Association of Research on the Biology of Liver...

Completed

Cetuximab + Gemox in Biliary Tract Cancer

Metastatic | Locally Advanced | Unresectable

Austria
Biond Biologics

Not yet recruiting

A Study of BND-35 in Participants With Advanced Solid Tumors

Cancer

Israel
Christopher Wilke

Recruiting

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design ((UPCI)13-056)

Squamous Cell Carcinoma

United States
University of Kansas Medical Center
Sanofi

Terminated

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Head and Neck Cancer | Carcinoma, Squamous

United States
US Oncology Research
Eli Lilly and Company; Oregon Health and Science University

Completed

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Androgen-independent Prostate Cancer

United States
Dartmouth-Hitchcock Medical Center

Completed

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer

Pancreatic Cancer
Baruch Brenner
Bristol-Myers Squibb; Merck Serono International SA

Recruiting

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Esophageal Squamous Cell Carcinoma

Israel
Shanghai Changzheng Hospital

Recruiting

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Colorectal Cancer

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck | Basaloid Squamous Cell Carcinoma | Undifferentiated Carcinoma | Adenosquamous Cell Carcinoma
Prof. Dr. Andreas Engert
The Clinical Trials Centre Cologne

Terminated

EMMA-1 (Erbitux for Multiple Myeloma) (EMMA-1)

Multiple Myeloma

Germany
Medical University of Vienna

Recruiting

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Head and Neck Squamous Cell Carcinoma

Austria
UNC Lineberger Comprehensive Cancer Center
Pfizer; Amgen

Active, not recruiting

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Colon Cancer | Colonic Cancer | Cancer of the Colon | Colon Neoplasms | Neoplasms, Colonic

United States
Pierre Fabre Medicament
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (NAUTICALCRC)

Metastatic Colorectal Cancer | BRAF V600E

China
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (HNO-2)

Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditions

Austria
Merck KGaA, Darmstadt, Germany

Completed

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (ADVANTAGE)

Squamous Cell Cancer

France, Italy, Spain, Germany, Hungary, Austria, Switzerland, Belgium, Poland
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (CACTUX)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Cancer of the Head and Neck

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Chordoma | Unresectable Malignant Neoplasm

United States
Eli Lilly and Company

Completed

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States, Canada
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Amgen

Completed

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Arthritis, Rheumatoid

United States, Germany, Bulgaria, Hungary, Poland, Estonia
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Kathryn Gold
Pfizer

Active, not recruiting

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
National Taiwan University Hospital

Unknown

Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer

Esophageal Cancer

Taiwan
Per Pfeiffer
Odense University Hospital

Withdrawn

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer (CECAVI)

Head and Neck Neoplasms

Denmark
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
University of Colorado, Denver

Completed

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Institute (NCI)

Completed

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Metastatic Colorectal Cancer

United States
Fox Chase Cancer Center

Terminated

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Colorectal Neoplasms

United States
State University of New York - Upstate Medical...
CTI BioPharma

Completed

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Carcinoma, Squamous Cell

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer

Anal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

Colorectal Cancer

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
University of Pittsburgh
Bristol-Myers Squibb

Completed

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

Cancer

United States
Charite University, Berlin, Germany

Unknown

Zevalin® First Line in Follicular Lymphoma

Follicular Lymphoma
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (APA)

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and Neck

United States
Mahidol University

Active, not recruiting

Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

Head and Neck Cancer | Locally Advanced

Thailand
Erasca, Inc.

Active, not recruiting

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

Metastatic Colorectal Cancer | Metastatic Pancreatic Ductal Adenocarcinoma

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Completed

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC (BTC)

Cholangiocarcinoma | Adenocarcinoma of Gallbladder

Taiwan

Search clinical trials for: Cetuximab (Erbitux®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations